Blood transfusion nursing is among the highest-stakes procedural skills in clinical practice. From verifying the right unit reaches the right patient, to catching a febrile reaction within the first 15 minutes, every step in the transfusion process carries direct life-or-death implications. NCLEX tests this content extensively because errors in transfusion practice are still a leading cause of preventable patient harm.
This guide covers every NCLEX-tested element: blood product types, pre-transfusion verification, IV access requirements, monitoring schedules, transfusion reactions in detail, the universal “stop the transfusion” protocol, massive transfusion, and documentation requirements.
Blood product types
Understanding what each product contains, why it is ordered, and how it must be handled is the foundation of safe transfusion practice.
| Blood product | Primary indication | Usual adult dose | Storage temperature | Maximum infusion time | Special considerations |
|---|---|---|---|---|---|
| Packed red blood cells (PRBCs) | Symptomatic anemia, acute blood loss (Hgb <7–8 g/dL or <10 g/dL in cardiac patients) | 1 unit (~250–350 mL); expect Hgb rise of ~1 g/dL per unit | 1–6°C (refrigerated) | 4 hours from issue | 18G or larger IV; Y-tubing with 0.9% NS only; never dextrose or LR |
| Platelets | Thrombocytopenia with active bleeding or pre-procedure (plt <50,000; prophylactic <10,000) | 1 apheresis unit or 4–6 pooled random-donor units | 20–24°C (room temp, agitated continuously) | 20–30 minutes per pool; max 4 hours from issue | Cannot refrigerate — cold activates platelets causing clumping. ABO compatible preferred but not always required. CMV-negative/irradiated for immunocompromised patients. |
| Fresh frozen plasma (FFP) | Coagulopathy (DIC, liver failure, warfarin reversal, massive transfusion), factor deficiencies when specific factor concentrate unavailable | 10–15 mL/kg (typically 2–4 units) | −18°C or colder (frozen); thawed at 37°C before infusion | 4 hours once thawed | Must be ABO compatible (contains plasma antibodies). Contains all clotting factors. Used in DIC and massive transfusion protocol (MTP). See the [DIC nursing guide](/nursing-tips/dic-nursing/) for coagulopathy management. |
| Cryoprecipitate | Fibrinogen deficiency (<100–150 mg/dL), von Willebrand disease, hemophilia A (when factor VIII concentrate unavailable), DIC | 10 units pooled (1 unit/10 kg); expect fibrinogen rise of 50–100 mg/dL per 10 units | −18°C or colder (frozen); thawed at 37°C | 4 hours once thawed; infuse rapidly (15–30 min) | Contains fibrinogen, factor VIII, factor XIII, vWF, fibronectin. Does NOT contain factor IX — not for hemophilia B. See [hemophilia nursing](/nursing-tips/hemophilia-nursing/) for factor replacement context. |
Key distinction for NCLEX: Platelets are stored at room temperature with continuous gentle agitation — refrigerating them destroys function. PRBCs are refrigerated. FFP and cryoprecipitate are frozen and must be thawed before use.
Pre-transfusion verification
The verification process is where most transfusion errors are preventable. Every step exists for a reason — a wrong-unit transfusion causes an acute hemolytic reaction that can kill within minutes.
Type and screen vs. crossmatch
Type and screen (T&S): Determines the patient’s ABO/Rh blood group and screens for unexpected alloantibodies in serum. Required before any transfusion. A T&S without crossmatch is valid for approximately 72 hours if no recent transfusion or pregnancy.
Crossmatch: Takes the patient’s serum and mixes it directly with the donor unit’s red cells to detect incompatibility. An immediate spin crossmatch takes 5–10 minutes. A full serological crossmatch takes 45–60 minutes and is required when the antibody screen is positive.
Emergency release: In hemorrhagic shock when there is no time for crossmatch, O-negative uncrossmatched blood is released immediately. O-negative is the universal donor for red cells (no A, B, or Rh antigens). Once the patient’s type is known, type-specific blood is issued.
Two-RN bedside verification (the critical safety step)
Before hanging any blood product, two licensed nurses must independently verify — at the bedside, with the patient — each of the following:
- Patient name matches exactly (ask patient to state name; do not read it to them)
- Patient date of birth matches
- Medical record number matches
- Blood type and Rh factor on unit matches patient’s type
- Crossmatch compatibility tag is attached and shows compatible
- Unit number on the bag matches the compatibility form
- Expiration date/time has not passed
- Blood bag integrity: no visible clots, unusual color, leaks, or bubbling
If any element does not match: do not hang the unit. Return it to the blood bank and clarify. This is non-negotiable.
Informed consent
Document that the patient (or surrogate) has provided informed consent for transfusion before the process begins. Jehovah’s Witness patients and other patients with religious or personal objections must have documented refusal and a care plan established with the provider.
IV access requirements
Minimum gauge for PRBCs: 18G peripheral IV catheter. Smaller gauges (20G, 22G) cause hemolysis as red cells are mechanically sheared through a narrow lumen, particularly when infusing under pressure. A 20G is acceptable in children where 18G is not feasible; expect slower infusion rates.
Central lines: A central venous catheter (CVC) or PICC line can be used for blood products. Confirm patency with a saline flush first. Do not use a luminal port that is running a vasoactive medication or TPN simultaneously — dedicate a lumen.
Tubing requirements:
- Use Y-type blood tubing with an in-line 170–260 micron filter (standard). The filter removes clots and microaggregates.
- Prime with 0.9% normal saline only. Dextrose solutions (D5W) cause hemolysis by creating a hypotonic environment. Lactated Ringer’s (LR) contains calcium, which chelates the citrate anticoagulant in stored blood and triggers clotting in the tubing — always contraindicated.
- Change tubing after every 4 hours or after every 2 units of PRBCs, whichever comes first.
- Never add medications to blood products or run medications in the same line concurrently.
For IV access technique, see the IV insertion nursing guide.
Transfusion initiation and monitoring
Starting the transfusion
- Obtain baseline vital signs (temperature, blood pressure, heart rate, respiratory rate, SpO2) immediately before hanging the unit.
- Start the transfusion slowly: 2 mL/min (approximately 50 mL/hr) for the first 15 minutes. This slow start allows early detection of severe reactions before a large volume is infused.
- Stay at the bedside for the entire first 15 minutes. The most dangerous reactions (acute hemolytic, anaphylactic) occur within minutes of starting. You cannot catch them from the nursing station.
- After 15 minutes, if no reaction: increase rate as ordered. A typical adult unit of PRBCs infuses over 2–3 hours. Maximum total hang time is 4 hours from issue (not from when you start — from when the blood bank released the unit).
Vital signs schedule
| Time point | Action |
|---|---|
| Before transfusion starts | Baseline VS |
| 15 minutes after start | VS check — most critical window |
| 30 minutes after start | VS check |
| 1 hour after start | VS check |
| End of transfusion | Final VS |
| Any symptom change | Immediate VS + assessment |
Temperature is the key vital sign. A rise of 1°C or more (1.8°F) suggests a reaction. Chills, flushing, back pain, or dyspnea at any point mean stop the transfusion immediately and assess.
Transfusion reactions
Transfusion reactions are the most heavily NCLEX-tested content in this topic. You need to know each type’s mechanism, onset, presentation, and nursing response — including which reactions allow you to restart the transfusion and which do not.
| Reaction type | Onset | Key symptoms | Mechanism | Nursing action | Can restart? |
|---|---|---|---|---|---|
| Febrile non-hemolytic (FNHTR) | 30 min – 6 hr into transfusion | Fever ≥1°C rise, chills, rigors, headache. No hemolysis. BP stable. | Recipient antibodies react against donor leukocyte antigens. Cytokine accumulation in stored blood also contributes. | Stop transfusion. Notify provider. Administer acetaminophen (not aspirin). Reassess. If fever resolves and provider confirms no hemolysis (DAT negative, urine clear), may restart at slow rate per provider order. | Sometimes — after evaluation confirms no hemolytic component, per provider |
| Acute hemolytic (AHTR) | Immediate to within 1 hr — may occur after just a few mL | Fever, chills, severe back/flank pain, dark red/brown urine (hemoglobinuria), hypotension, tachycardia, sense of impending doom. DIC can develop. | ABO incompatibility — patient's antibodies (anti-A, anti-B) activate complement and destroy donor RBCs intravascularly. Most often due to clerical/identification error. | STOP transfusion immediately. Disconnect blood tubing at patient — do not flush blood into patient. Keep IV patent with NS. Notify provider STAT. Save blood bag and tubing (send to blood bank). Draw labs: CBC, BMP, LDH, haptoglobin, DAT, repeat type & screen. Send first-void urine. IV fluids to maintain urine output ≥1 mL/kg/hr to prevent renal tubular injury. Monitor for DIC, shock, renal failure. | Never — never restart this unit or any unit until the error is investigated |
| TRALI (Transfusion-Related Acute Lung Injury) | Within 6 hours of transfusion start (most within 1–2 hr) | Acute dyspnea, hypoxia (SpO2 drop), bilateral pulmonary infiltrates on CXR (white-out pattern), fever. No evidence of cardiac cause (no elevated BNP, no JVD, no HTN). Resembles ARDS. | Donor plasma contains anti-HLA or anti-HNA antibodies that activate recipient neutrophils, causing capillary leak in the pulmonary vasculature. | STOP transfusion. Notify provider. Supplemental O2 — many patients require high-flow or mechanical ventilation. Supportive care: no diuresis (unlike TACO). Report to blood bank — the implicated donor is removed from future donations. | Never |
| TACO (Transfusion-Associated Circulatory Overload) | During transfusion to within 6 hours; more common in elderly, heart failure, renal failure, small body size | Dyspnea, orthopnea, hypertension (key differentiator from TRALI), tachycardia, elevated JVD, S3 gallop, bilateral crackles, elevated BNP. CXR: bilateral infiltrates with cardiomegaly. | Volume overload — the transfused volume exceeds the patient's circulatory capacity, causing hydrostatic pulmonary edema. It is a fluid overload problem, not an immune problem. | Slow or stop transfusion per provider. Sit patient upright. Administer diuretic (furosemide) as ordered. Supplemental O2. Consider slower transfusion rate for future units in at-risk patients. Premedication with furosemide may be ordered in high-risk patients. | Sometimes — may resume at a slower rate once stabilized, per provider |
| Anaphylactic | Within seconds to minutes — may occur after <10 mL | Urticaria, pruritus, bronchospasm, stridor, angioedema, hypotension, tachycardia, loss of consciousness. Fever is usually absent. | IgA-deficient patients who have anti-IgA antibodies react to IgA in donor plasma. Also occurs with hypersensitivity to other plasma proteins. | STOP transfusion immediately. Call for help. Epinephrine 0.3–0.5 mg IM (anterolateral thigh). Airway management — prepare for intubation. IV fluids for hypotension. Diphenhydramine, corticosteroids as adjuncts. Future transfusions: washed RBCs (plasma removed) or IgA-deficient donor blood. | Never |
| Delayed hemolytic (DHTR) | 3–14 days post-transfusion | Unexplained falling hemoglobin, low-grade fever, jaundice, positive DAT. Rarely causes hemoglobinuria or hemodynamic instability. | An anamnestic (recall) immune response — patient was previously sensitized to a red cell antigen (from prior transfusion or pregnancy). Antibody titer was undetectable at crossmatch but rises rapidly after re-exposure. | Notify provider. Obtain repeat type & screen, DAT, CBC, LDH, bilirubin. Usually self-limiting. Future transfusions require antigen-negative units for the implicated antigen. | N/A — occurs after transfusion is complete |
| Allergic (mild) | During transfusion | Urticaria, pruritus, flushing. No systemic involvement. Vitals stable. | IgE-mediated reaction to plasma proteins in donor blood. | Stop transfusion. Administer diphenhydramine (Benadryl) as ordered. Reassess. If symptoms resolve completely and vitals stable, provider may order restart. | Sometimes — after symptoms fully resolve, per provider order |
The “stop the transfusion” universal protocol
When any adverse reaction is suspected — whether mild urticaria or suspected hemolysis — the sequence is always:
- Stop the transfusion — close the blood tubing clamp immediately
- Disconnect blood tubing at the patient’s IV site — do not flush blood forward into the patient
- Keep the IV patent — attach NS and keep the line open for medications and fluids
- Notify the provider immediately — describe symptoms and vital signs
- Save the blood bag, IV tubing, and any remaining blood — send to the blood bank for analysis; the unit number must be cross-referenced
- Obtain urine — look for hemoglobinuria (dark, tea-colored urine indicating intravascular hemolysis)
- Draw labs as ordered: CBC, BMP, coagulation panel, LDH, haptoglobin, DAT, repeat type & screen
- Document everything — time reaction noted, symptoms, vital signs, interventions, provider notification time
NCLEX critical point: You do not restart the transfusion, call the blood bank, or draw labs first. You stop first, always.
Blood warmer indications
A blood warmer (inline device that heats blood to body temperature during infusion) is indicated in:
- Massive transfusion — infusing large volumes of refrigerated blood rapidly causes hypothermia, which worsens coagulopathy and cardiac arrhythmias (the “lethal triad” of trauma: hypothermia, acidosis, coagulopathy)
- Cold agglutinin disease — patient’s antibodies agglutinate at low temperatures; warming prevents intra-transfusion hemolysis
- Neonates and premature infants — unable to generate sufficient body heat; cold blood causes hypothermia
Never warm blood in a microwave or with hot water. Only use FDA-approved blood warming devices with temperature monitors. Overheating causes hemolysis.
Massive transfusion protocol (MTP)
MTP is activated in life-threatening hemorrhage (typically defined as >10 units PRBCs in 24 hours, or >4 units in 1 hour, or ongoing uncontrolled hemorrhage).
1:1:1 ratio: PRBCs : FFP : Platelets in a 1:1:1 ratio approximates whole blood and prevents dilutional coagulopathy. Without adequate FFP and platelets, transfusing only PRBCs dilutes clotting factors and worsens bleeding.
Permissive hypotension: In trauma patients before surgical hemorrhage control, target systolic BP ~80–90 mmHg (not normal) to prevent clot disruption at injury sites. Once hemorrhage is surgically controlled, normalize BP. This does not apply to traumatic brain injury patients, who need higher perfusion pressure.
Nursing priorities during MTP:
- Prepare for rapid infusion — pressure bags or rapid infuser devices
- Monitor temperature: blood warmers mandatory
- Draw labs every 30–60 minutes: CBC, PT/INR, fibrinogen, ionized calcium
- Calcium replacement: citrate (the anticoagulant in stored blood) chelates calcium. With massive transfusion, citrate toxicity causes hypocalcemia → cardiac arrhythmias, decreased cardiac contractility. Monitor ionized calcium and replace as ordered.
- Communicate with blood bank continuously — they maintain the ratio supply ahead of bedside need
For hypovolemic shock management, see the shock nursing guide.
Nursing documentation requirements
Document the following for every transfusion:
- Pre-transfusion: Two-RN verification (both nurses’ names, time), patient consent, baseline vitals, IV access site and gauge, blood product type and unit number, start time
- During transfusion: Vital signs at each required interval, patient tolerance, rate adjustments, any symptoms noted
- If a reaction occurs: Time of symptom onset, description of symptoms, vital signs at time of reaction, interventions taken (including what was stopped, when, and what NS rate was started), provider notification time, provider name, orders received, unit and tubing disposition, labs drawn
- Post-transfusion: End time, total volume infused, final vital signs, patient response
Patients requiring special blood products
Leukoreduced blood: Filtered to remove white blood cells. Standard for most patients now. Reduces febrile non-hemolytic reactions and CMV transmission.
Irradiated blood: Blood is irradiated with gamma rays to destroy donor T-lymphocytes, preventing transfusion-associated graft-versus-host disease (TA-GvHD). Required for immunocompromised patients (bone marrow transplant recipients, neonates, Hodgkin’s lymphoma patients, patients receiving purine analogs like fludarabine). TA-GvHD has >90% mortality.
CMV-seronegative blood: For CMV-negative immunocompromised patients (transplant recipients, HIV patients, neonates of seronegative mothers) — prevents CMV primary infection via transfusion. Leukoreduced blood is considered CMV-safe equivalent.
Washed RBCs: Plasma removed by washing; used for IgA-deficient patients, severe allergic reactions to plasma proteins.
Patients with anemia may require repeated transfusions and benefit from evaluation for iron deficiency before ongoing transfusion dependence. Patients with thrombocytopenia requiring platelet transfusions should be evaluated for platelet refractoriness (failure of platelet count to rise after transfusion — suggests alloimmunization).
NCLEX tips
- The first action when any transfusion reaction is suspected: stop the transfusion. Before calling the provider, before drawing labs, before anything else — close the clamp.
- Lactated Ringer’s is absolutely contraindicated with blood products. Calcium in LR chelates citrate anticoagulant → clots form in tubing. Only 0.9% NS is compatible.
- Never transfuse beyond 4 hours from issue. After 4 hours, bacterial proliferation risk becomes unacceptable. If a unit is not infused in time, it must be discarded.
- Two licensed nurses must verify at the bedside before starting. Not one. Not at the nurses’ station. Bedside, together, with the patient.
- TRALI looks like ARDS; TACO looks like pulmonary edema. The key differentiator: TACO patients are hypertensive; TRALI patients are not. TACO patients improve with diuresis; TRALI patients do not.
- Acute hemolytic reaction is the most dangerous — it can occur after just a few milliliters of ABO-incompatible blood. The mechanism is complement activation and intravascular hemolysis, causing renal failure, DIC, and death.
- Febrile non-hemolytic reaction is the most common — managed with stopping the transfusion and acetaminophen. It can sometimes be resumed after evaluation.
- Anaphylaxis in IgA-deficient patients — these patients lack IgA entirely and have pre-formed anti-IgA antibodies. Even trace IgA in donor plasma triggers anaphylaxis. Future transfusions must use washed or IgA-deficient donor blood.
- Flank pain + dark urine + fever = acute hemolytic reaction until proven otherwise. Stop immediately.
- Platelets at room temperature. Refrigerating platelets causes cold-induced activation and clumping, rendering them non-functional. This is why platelet shelf life is only 5–7 days — room temperature storage increases bacterial contamination risk.
- 18G minimum for PRBCs. Smaller gauge causes mechanical hemolysis. In an emergency, a 20G is a compromise, not a standard.
- Citrate toxicity in massive transfusion — citrate binds ionized calcium → hypocalcemia → arrhythmias, decreased cardiac output, muscle tetany. Monitor ionized calcium and replace proactively.
- Irradiated blood for immunocompromised patients — prevents TA-GvHD, which carries >90% mortality. Do not confuse irradiated blood (removes T-lymphocytes) with washed blood (removes plasma).
- First 15 minutes: nurse stays at bedside. The most severe reactions occur early and require immediate recognition and intervention.
- Document two-RN verification names and time — this is both a legal requirement and a safety checkpoint that NCLEX tests directly.
Sources
- AABB (American Association of Blood Banks): Technical Manual, 21st edition — blood product storage, transfusion administration standards, reaction investigation protocols
- FDA guidance: Guidance for Industry: Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components and transfusion safety publications
- StatPearls (NCBI): Transfusion Reactions (NBK482202); Blood Product Transfusion (NBK560533); TRALI (NBK459166); TACO (NBK560558)
- PubMed: Clifford L et al. “Characterization of Transfusion-Associated Circulatory Overload” (PMID 25614244); Toy P et al. “Transfusion-related acute lung injury: incidence and risk factors” (PMID 22076041)
- NCSBN NCLEX-RN Test Plan: Pharmacological and Parenteral Therapies — Blood and Blood Product Administration
- Joint Commission National Patient Safety Goals: Blood transfusion safety and patient identification (NPSG 01.01.01)